From BMI 30: Detachment From the Cash Register? AOK Boss Warns of Billions of Dollars
6 Articles
6 Articles
Weight loss sprays such as Wegovy and Mounjaro could also become a topic for the statutory health insurance companies in the future. However, a cost assumption might have huge financial consequences. The AOK warns against burdens in billions.
AOK CEO Carola Reimann is critical of the acquisition of weight loss syringes in severe obesity. The statutory health insurance companies will have to pay billions of euros.
According to the AOK-Bundesverband (Federal Association of Health Insurance Association), taking over the costs of weight loss injections could burden the statutory health insurance (GKV) with billions of euros in the extreme case. If all GKV-insured obesity patients were treated with it regularly with a body mass index (BMI) of 30 or more, an annual cost of approximately 45 billion euros would be calculated, said AOK head Dr. Carola Reimann to …
Treatment with weight loss syringes such as Wegovy or Mounjaro costs several hundred euros a month and usually has to be paid by itself. A cost assumption could burden the GKV with billions.
Treatment with weight loss syringes such as Wegovy or Mounjaro costs several hundred euros a month. A cost assumption could burden the GKV with billions.
Reimbursement for weight-loss injections could, in an extreme case, burden statutory health insurance (GKV) with billions of euros. If all GKV-insured obese patients with a body mass index (BMI) of 30 or higher were regularly treated with these injections, the projected annual costs would amount to approximately 45 billion euros, AOK Federal Association CEO Carola Reimann told the newspapers of the Funke Media Group. This is certainly a worst-ca…
Coverage Details
Bias Distribution
- 50% of the sources lean Left, 50% of the sources lean Right
Factuality
To view factuality data please Upgrade to Premium
